FDA Warns GLP-1 Drugs of Risk for Rare Vision Loss Condition
FDA requires vision loss warnings for GLP-1 weight-loss drugs
Clinical trials show an incidence rate of 6.4 cases per 100,000 patient-years among GLP-1 users, compared to 3.8 for other treatments or placebos.
Patients are advised not to discontinue medications independently, but to seek immediate medical evaluation for sudden, painless vision changes.
Popular weight-loss and diabetes medications must now carry updated safety information regarding a rare eye condition capable of causing permanent vision loss, oregonlive.com reported. The Food and Drug Administration issued the requirement for all GLP-1 drugs in a drug safety communication.
Affected medications and the targeted eye condition
The regulatory action impacts widely prescribed medications including Ozempic, Wegovy, Mounjaro, and Zepbound. The required warning addresses nonarteritic anterior ischemic optic neuropathy, known as NAION.
The condition occurs when blood flow to the optic nerve is reduced. ABC News reported that NAION can cause sudden, painless vision loss, typically affecting one eye. Medical science currently offers no known treatment capable of reversing vision already lost to the condition.
Clinical trials show higher NAION rates among GLP-1 users
Despite the severity of the potential outcome, regulatory agencies note that NAION remains rare. The updated warning does not establish a definitive causal link between GLP-1 medications and the condition.
An analysis of 126 clinical trials involving more than 134,000 patients found 6.4 cases per 100,000 patient-years among GLP-1 users. This compares with 3.8 cases per 100,000 patient-years among individuals receiving other treatments or placebos, according to CNBC.
Scrutiny regarding a possible connection intensified following research published in 2024. A study published in JAMA Ophthalmology identified an association between semaglutide prescriptions and a higher risk of NAION. Subsequent investigations by various researchers have produced mixed results, prompting ongoing scientific study.
Guidance for patients and prescribing physicians
Health authorities stress that individuals should not discontinue their prescribed medication regimen without consulting a medical professional. The FDA advises patients to contact a healthcare provider immediately if they experience sudden, painless vision loss or other new visual disturbances.
Medical providers are directed to expedite referrals for patients presenting with suspected NAION to qualified eye specialists for comprehensive evaluation.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.